Biofrontera (BFRIW) Stock Price, News & Analysis

Company Overview

Biofrontera AG is a biopharmaceutical company headquartered in Leverkusen, Germany, specializing in the development, manufacture and commercialization of dermatology products. Founded in 1997, the company focuses on therapies for skin diseases through innovative drug and device combinations. Its core business centers on photodynamic therapy, where a photosensitizing agent is activated by a specialized light source to treat precancerous and cancerous skin conditions.

The company’s flagship product, Ameluz, is a topical formulation of aminolevulinic acid used in conjunction with the BF-RhodoLED irradiation device. This product duo is approved in Europe and the United States for the treatment of actinic keratosis and superficial basal cell carcinoma. Biofrontera also markets other dermatological products in selected markets, working with distribution partners to reach patients across key regions.

Biofrontera serves markets in the European Union, the United States and other territories through a combination of direct sales operations and strategic partnerships. The company’s US subsidiary, established in 2016, supports clinical development and commercialization efforts in North America. Its management team comprises experienced professionals in pharmaceutical development, regulatory affairs and specialty dermatology.

Key Stats

• Today's Range: $0.11 to $0.11
• 50-Day Range: $0.10 to $0.20
• 52-Week Range: $0.02 to $0.28
• Volume: N/A
• Average Volume: 12,015 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BFRIW Stock Analysis - Frequently Asked Questions

How have BFRIW shares performed this year?

Biofrontera's stock was trading at $0.0607 at the beginning of 2025. Since then, BFRIW stock has increased by 75.8% and is now trading at $0.1067.

How do I buy shares of Biofrontera?

Shares of BFRIW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BFRIW
• CIK: 1858685
• Web: www.biofrontera-us.com
• Phone: 781-245-1325
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $39.19 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A